Clinical Trial Update: Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting

View source ↗

Summary

The clinical trial evaluating an exosomal signature for predicting occult liver metastasis in pancreatic ductal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: City of Hope Medical Center | Conditions: PDAC - Pancreatic Ductal Adenocarcinoma | Status: COMPLETED